Podcasts about zepbound

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There's tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX   This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real.   "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. https://medicalxpress.com/news/2025-08-diabetes-children-linked-parents.html XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don't take any medical actions based on the app's output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it's now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I'll link his story up in the show notes. Diabetes Center Berne provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards.  Comerge AG , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. Dexcom graciously conducted the Human Factors study to ensure safety and accuracy.  ​ ​T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin's glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin's ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area.   “This discovery changes how we think about metformin,” Fukuda said. “It's not just working in the liver or the gut, it's also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.”     https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/   XX Looks like GLP-1 pills are moving ahead. Lilly says it's version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. https://www.usatoday.com/story/news/health/2025/08/26/lilly-glp-1-pill-weight-loss/85830686007/ XX     An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S.   "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services."         https://www.medpagetoday.com/primarycare/diabetes/117151 XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google's corporate parent. Verily's work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” https://timesofsandiego.com/business/2025/08/27/report-life-sciences-firm-dexcom-lay-off-200-san-diego-workers/ XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet's new growth organization. The appointments are some of CEO Ashley McEvoy's first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call:   enhancing the company's commercial capabilities, building Insulet's brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. https://www.medtechdive.com/news/insulet-eric-benjamin-manoj-raghunandanan-appointments/758668/ XX   XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said.   https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/

Today we're revisiting our conversation with one of the greatest athletes of all time, Serena Williams, who just made news with Vogue by opening up about using GLP-1 Zepbound after her pregnancy. Almost three years ago, she made news again when she announced she's taking a step back from tennis in the September issue of Vogue. In our first-ever episode of The Run-Through, Serena shared what life looks like post-tennis; everything from being a mom, a VC with Serena Ventures and a children's book author. The Run-Through with Vogue is your go-to podcast where fashion meets culture. Hosted by Chioma Nnadi, Head of British Vogue; Chloe Malle, Editor of Vogue.com; and Nicole Phelps, Director of Vogue Runway, each episode features the latest fashion news and exclusive designer and celebrity interviews. Learn about your ad choices: dovetail.prx.org/ad-choices

It's nearly impossible to turn on the television or open a magazine without seeing advertisements for the latest weight loss trend: GLP-1 medications, commonly known as Ozempic, Mounjaro, Wegovy, and Zepbound. Approximately 15 million people are estimated to have tried these drugs for weight loss. However, as with any emerging health trend, it's important to consider whether these medications are safe and cost-effective.What are the risks and benefits of these drugs? Is the pharmaceutical industry providing a quick fix for the approximately 42% (or 100 million) U.S. citizens who are obese? Are these medications the only solution to the obesity epidemic, or are lifestyle and dietary changes essential for long-term success? Dr. Nicole Dorotik joins us in this episode to address these questions and more as we explore the latest trends in the pursuit of health and wellness.Special Guest: Dr. Nicole Dorotik Dr. Nicole Dorotik earned her medical degree from the University of Arizona College of Medicine and completed her residency at Long Beach Memorial Hospital in Long Beach, California. She is board-certified in Family Medicine and has over 20 years of clinical experience. Along with her professional accomplishments, Nicole is the proud mom to three great kiddos. Show notes:Weight Comes Back When You Stop Taking Drugs Like Ozempic, Study Finds.https://www.sciencealert.com/weight-comes-back-when-you-stop-taking-drugs-like-ozempic-study-finds#A new era of weight loss: Mental health effects of GLP-1 drugs.https://www.apa.org/monitor/2025/07-08/weight-loss-drugs-mental-healthRx History: The Rise of GLP-1s.https://www.innovativerxstrategies.com/rx-history-glp1s/Unintended consequences: Weight loss drugs are changing the way consumers buy groceries.https://www.post-gazette.com/business/healthcare-business/2025/08/17/glp1-ozempic-grocery-store-food-price-weightloss/stories/202508070069.

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Today is a Plus SideZ Rewind! Two years ago, we sat down with the one and only Rosie O'Donnell at the dawn of our movement for affordable access to GLP-1 medications & ending the stigma around treating obesity as a disease. Now, as we stand well into season five with thousands of new subscribers, so it's time for a little time-travel! We're bringing you a “Rewind” of that pivotal conversation to let our new listeners hear where it all began and let our longtime supporters see just how far we've come.In this flashback, we revisit that summer of 2023 when the Mounjaro $25 Savings Card Coupon was ending and people were flocking to compound GLP-1 which still had a lot of question marks surrounding it. And the shortage of all GLP-1s was growing. There was no Zepbound or cash pay price or branded vials. It was $1400-1000 a month go get access to branded GLP-1s. With more voices in the conversation today, we're measuring our progress from that. Oh how far we've come! We can now get branded GLP-1 for under $500. That's a ton of movement in a short time. But let's get it lower! Keep the faith. Let's get loud AND change things! ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Send us Fan Mail!Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Think sleep apnea is just about loud snoring? Think again. This common condition is a serious health issue that affects a staggering number of people with both type 1 and type 2 diabetes. In this eye-opening episode, Dr. Steve Edelman is joined by Dr. Jeremy Pettus, who shares his own recent and unexpected diagnosis of obstructive sleep apnea. From recognizing the subtle symptoms to navigating the diagnosis process and starting treatment, Dr. Pettus offers a firsthand account of what it's like to confront this underdiagnosed condition. This episode is a crucial wake-up call, revealing how untreated sleep apnea can impact everything from your heart health and blood pressure to your energy levels and insulin resistance. Whether you or a loved one has diabetes, this is essential listening.Key Topics:What is Sleep Apnea? An explanation of how the airway collapses during sleep, leading to a drop in oxygen levels and triggering a "fight-or-flight" response throughout the night.Symptoms to Watch For: A breakdown of the classic signs, including loud snoring and gasping for air, as well as less obvious daytime symptoms like excessive fatigue, morning headaches, and low libido.Who Is at Risk?: A look at the surprisingly high prevalence of sleep apnea, especially among people with diabetes, affecting up to 80% of those with type 2 and half of those with type 1.Key Risk Factors: A guide to the factors that increase your chances of developing sleep apnea, such as weight, neck size, age, gender, and lifestyle habits like alcohol consumption.Getting Tested: An overview of the diagnostic process, from the simple STOP-BANG screening questionnaire to the modern convenience of home sleep tests.Effective Treatment Options: A comprehensive look at treatments that can improve your health, including lifestyle changes, CPAP therapy, and the new FDA-approved use of weight-loss medications like Zepbound for sleep apnea. ★ Support this podcast ★

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

People are losing their minds over Cracker Barrel, Eli Zaret joins us as the Detroit Tigers are on fire, Kirk Herbstreit cries again, Magnum P.I.G., Lil Naz X nuts, Jizzlaine Maxwell's DOJ interview, and Diamond David Lee Roth is always the showman. Kirk Herbstreit is a bumbling mess discussing Lee Coso retiring. Eli Zaret drops by to discuss Magnum P.I. Day at Comerica Park, the surging Detroit Tigers, Pitcher Drew Sommers debut, the Detroit Lions Super Bowl odds, Jason Benetti's many hats, the Lions 53-man roster, Shilo Sanders BLOWN OUT, CFB is back, more sports dildos and more. Warning: Fox 2 Stephanie Mead thirst trap. Cracker Barrel changed their logo and people are melting down. Steak ‘n Shake is on the attack. Michael Strahan gave the CEO time to do a commercial on Good Morning America. Marc loves the McDonaldland Meal… if the employee knows what it is. Halsey defends her movie Americana, which bombed at the box office. Lil Nas X has lost his mind and his clothes. SNL is ready to make some changes. Donald Trump's hands look old… cause he's old. Morgan Wallen is boycotting The Grammy's but won't say why. Jay-Z is really loaded. He the richest musician in history. Male cheerleaders are now getting backlash despite being around for quite a while. David Lee Roth is sounding awful lately. Like REALLY bad. Hold me closer, Tony Danza! Serena Williams is getting crap for taking the fat shot… and doing a commercial for Zepbound. Hey Amanda Bynes… why you look different? These brothers totally got it on. Travel with Livii has some pretty incredible travel requests. Jizzlaine Maxwell spills. Prince Andrew, Bill Clinton and Donald Trump are cleared of wrongdoing… yeah right. Donald Trump gets a victory over Letitia James. She'll appeal it. John Bolton was raided on Friday. Britney Spears remains crazy. Jenelle Evans claims to have made over $1.5M on OnlyFans. She's at odds with her son, Jace. Lil Tay calls out every woman over 25 who is not rich. Jeff Bezos wants his wife to be the next Bond Girl. If you'd like to help support the show… consider subscribing to our YouTube Channel, Facebook, Instagram and Twitter (Drew Lane, Marc Fellhauer, Trudi Daniels, Jim Bentley and BranDon).

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. Now, in most industries, if a product goes viral like this, it's a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.In theory, anyway. But, what if that explosive demand backfired, opening the door to legal knock-offs? You've maybe seen them - copycats advertised as the same thing as Ozempic. So, what's the difference? And just how legal are they? On today's show - a drug that's changing people's lives is also challenging the traditional way we buy and sell medicine.This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money's executive producer.Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

See omnystudio.com/listener for privacy information.

If injectable weight loss drugs like Zepbound can help people lose 20% of their weight, what about a once-a-day pill that achieves 12% weight loss, without the needles and sky-high cost? In this episode, Lisa Oldson, MD shares Andrea's journey through the maze of weight loss medications and introduces the promising new drug orforglipron. You'll hear how this oral GLP-1 agonist compares to popular injectables, why it could be a game-changer for millions, and the top five reasons to consider medication as part of a comprehensive weight loss plan. Whether you're curious about new treatments, concerned about side effects, or looking for affordable options, this episode breaks down what you need to know about orforglipron and the future of weight loss medicine.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter by emailing us at Team@SmartWeightLossCoaching.com, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

Wellness is more than weight, and health is more than numbers. In this episode of BHT Bytes, host Sharlee Dixon is joined by Peter Fenger to unpack the complex intersections of diet culture, body image, and mental health. From the rise of weight-loss fads in the '80s and '90s to the emergence of body positivity and fat visibility movements, we trace how cultural messages about size and health have shaped generations. The conversation dives into the psychological toll of diet culture—covering disordered eating, negative self-image, and the mental health struggles tied to societal ideals. We also explore the new wave of GLP-1 weight-loss drugs like Ozempic, Wegovy, and Zepbound—hailed by some as groundbreaking, but raising critical questions about identity, stigma, and long-term impact. Together, Sharlee and Peter break down the science, the stigma, and the shifting narratives of weight and wellness in today's world.   Follow Behavioral Health Today on Instagram at: https://www.instagram.com/behavioralhealthtoday/ Follow us on TikTok at: https://www.tiktok.com/@behavioralhealthtoday Follow us on Threads at: https://www.threads.net/@behavioralhealthtoday Or watch us live on YouTube at: https://www.youtube.com/channel/UCvOeCMGsF7B2gNBHuWxt-fQ

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Join us as we chat with Dr. Spencer Nadolsky, founder of Sequence (now part of Weight Watchers), about the real-world journey of living with GLP-1 medications like Wegovy and Ozempic. We dive into the stages of this journey—why weight regain can happen, how to navigate plateaus, and how to rethink exercise and food tracking without the guilt. Dr. Spencer breaks down why obesity is truly a chronic condition and offers down-to-earth advice on managing each phase. It's all about understanding the path, avoiding common pitfalls, and feeling empowered on your GLP-1 journey_______________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Send us Fan Mail! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

In this episode, Mike discusses the latest GLP-1 craze, which has to do with healthy weight individuals using these medications. ------------------------------------------------Click here to apply for coaching!For some amazing resources and to be a part of a badass community, join our FB group HEREThe personality assessment is now available online! Click here to take the assessment and find out what your personality tells us about the way you should be training and eating.Take the assessment here!To learn more about Neurotyping, visit www.neurotypetraining.comFollow Mike on IG at @coach_mike_millner

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the recent changes in obesity medication coverage, particularly focusing on the CVS Caremark decision to drop ZEPBound from their formulary in favor of Wegovi. They explore the implications of this decision for patients and providers, the role of pharmacy benefit managers (PBMs) in healthcare, and the ongoing advocacy efforts to ensure access to effective obesity treatments. The conversation highlights the complexities of insurance coverage, the need for patient-centered care, and the importance of making medications more affordable.- The recent changes in obesity medication coverage have raised concerns among providers and patients.- CVS Caremark's decision to drop ZEPBound has sparked a petition advocating for better access to medications.- Pharmacy Benefit Managers (PBMs) play a significant role in determining medication coverage and costs.- There is a need for more nuanced insurance policies that consider patient needs and clinical severity.- Advocacy efforts are crucial in reversing negative trends in medication coverage.- Patients often face challenges with prior authorization processes when switching medications.- The cost of obesity medications is a significant barrier to access for many patients.- Insurance companies are increasingly dropping coverage for anti-obesity medications, impacting patient care.- The conversation emphasizes the importance of patient-centered care in obesity treatment.- There is a call for making obesity medications more affordable and accessible to patients.https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationClick to join Dr. Spencer's online clinic if you need help with this 

Why does joy feel so scary? Why do we hold back when life is good, waiting for something bad to happen? In this episode, I'm sharing why joy is the most vulnerable emotion we can feel and how that fear keeps us from fully living. We'll talk about why our brains default to “what if it all goes wrong,” how this ties into body image and weight loss, and why you don't need a smaller body to feel joy right now.I'm also giving you a personal update from my birthday and what's making me grateful (and a little nervous!) in this season of life. If you've ever struggled to let yourself be happy without guilt or fear, this one's for you.What you'll learn in this episode: ✔ Why joy is the most vulnerable emotion ✔ How fear of losing happiness sabotages your peace ✔ The connection between body image, weight loss, and joy ✔ Practical tips to embrace joy without waiting for the “perfect” moment

Welcome to Ozempic Weightloss Unlocked, your source for the latest insights on Ozempic—from medical updates to its real-world impact on health and lifestyle.Ozempic, also known as semaglutide, was originally designed to help manage type 2 diabetes, but it has quickly become a leading medication for weight loss. Clinical studies highlighted by Medical News Today and Drugs.com have shown that people using Ozempic can lose between 10 and 17 percent of their body weight over about 68 weeks, with results varying based on dosage and individual response. Some individuals have reported losing as much as 30 pounds in just six months, while also seeing significant improvements in blood sugar levels, such as A1C reductions from 8.5 to 6.2, according to user reviews.But what sets Ozempic apart from other medications like metformin? While both can have modest effects on body weight, Ozempic generally leads to more substantial results. According to Drugs.com, participants in trials with Ozempic and lifestyle changes lost an average of nearly 15 to 17 percent of their weight, far exceeding the modest results commonly seen with metformin.The mechanism is fascinating—Ozempic works by imitating a hormone called GLP-1, reducing appetite and slowing digestion. Yet with such rapid and notable weight loss comes important questions about long-term health. A new study from the University of Virginia, as reported by Science Daily, warns that while GLP-1 drugs like Ozempic deliver dramatic fat loss, they do not appear to improve crucial measures of cardiorespiratory fitness. Moreover, muscle loss is a real concern. Researchers have documented reductions in lean mass when using Ozempic for substantial weight loss, which could impact strength, posture, and even risk of heart problems. To counter this, doctors increasingly recommend combining Ozempic with exercise and a protein-rich diet to help maintain muscle and overall health.With these dramatic results, it's not surprising that Ozempic and similar GLP-1 drugs are making waves far outside strictly medical circles. Weight loss clinics nationwide are rethinking their programs to include these medications, as South County Medspa and Wellness notes, allowing many patients to expect a 10 to 15 percent reduction in body weight over several months. However, these treatments do not come cheap—monthly costs can reach several hundred dollars, leading to high rates of discontinuation as users stop due to expense or side effects, which can include nausea and digestive issues.And what happens if you stop Ozempic? As Professor Patricia Brubaker explains for McGill University, stopping the medication often results in some weight regain—a typical rebound of about 12 percent of what was lost—but most people still hold on to some of their original weight loss a year later. It's not quite the dreaded "yo-yo" effect, but it does highlight the importance of ongoing therapy or lifestyle modification for lasting results.In the realm of new developments, tirzepatide, branded as Zepbound, stands out as the only FDA-approved medication demonstrating even greater weight loss, with some participants losing up to 22 percent of their body weight. Meanwhile, the rise of so-called GLP-1 supplements online is causing concern among Harvard experts. According to Harvard T.H. Chan School of Public Health, these over-the-counter products are not regulated or proven effective, so listeners should approach them with skepticism.As the science evolves and new studies emerge almost weekly, there is a growing recognition among experts: medications like Ozempic can be powerful tools for weight loss, but to truly unlock healthier living, they should be paired with exercise, nutrition, and long-term, individualized care.Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you never miss the latest updates and expert insights. This has been a Quiet Please production, for more check out quietplease dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered why getting obesity medications like Wegovy or Zepbound feels sooo complicated and honestly, kinda impossible sometimes?Between high costs, confusing insurance rules, and endless paperwork, even patients who qualify often struggle to actually start treatment.To help us break it all down, I'm joined by Dr. Nikita Shah, a board-certified obesity medicine physician and founder of WeightSense in Orlando, Florida. She focuses on practical, health-first weight care and also serves on the Medical Society of Central Florida board and the Obesity Pillars Journal editorial board. She's all about helping patients find real-world solutions that actually work.In this episode, we cover everything you need to know about accessing obesity medications, including:Why obesity is a real medical condition, not a personal failure.How cost and insurance create the biggest hurdles.The different coverage rules for medications like Wegovy, Zepbound, and Ozempic.What prior authorization really involves—and how to get through it.Affordable medication options like Qsymia and Contrave.Why most compounded anti-obesity medications aren't the safest choice.If you're ready to finally understand the process, cut through the confusion, and learn the smartest steps to get started, listen to the full episode now!Connect with Dr. Shah:Instagram: nikitashahdoWebsite: Weight SenseBlog Mentioned: Understanding Insurance CoverageConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

When it comes to weight loss, the scale isn't the only thing that changes—your reflection and self-image often transform too. In this episode, I talk about a topic gaining attention in the media and social circles: "Ozempic face" and the emotional and physical effects of rapid weight loss, especially for those using GLP-1 medications like Wegovy, Zepbound, or Ozempic. I share a story about a friend who hesitated to increase her dosage due to concerns about skin changes, which opened the door to a larger discussion on body image during weight loss. I explain that these facial and skin changes—such as sagging, wrinkles, or looking more tired—aren't exclusive to medication use but are common with any significant weight loss, especially as we age.  Furthermore, I walk through ways to manage these concerns, like slowing down weight loss, prioritizing resistance training and protein, staying hydrated, considering aesthetic treatments, and most importantly, shifting focus from appearance to overall health. I emphasize the importance of support, tuning out unsolicited comments, and curating a healthier social media feed.  If you're navigating weight loss and struggling with body image changes like "Ozempic face," listen to this empowering episode for real talk, expert tips, and compassionate support on your journey.   Episode Highlights: What “Ozempic face” really means and why it happens Emotional impact of rapid weight loss and changing appearance How to manage body image concerns during weight loss Practical tips: strength training, hydration, and pacing weight loss Cosmetic treatment options and when to consider them The role of social media in shaping unrealistic expectations Reframing the focus from appearance to overall health and wellness Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode of the Pound of Cure Weight Loss Podcast, Dr. Matthew Weiner and registered dietitian Zoë dive deep into the latest research on GLP-1 medications and their evolving role in weight loss, muscle preservation, and even potential cancer treatment.They break down what the newest studies actually show — including why so many headlines are misleading, and how to interpret scientific research through a more critical lens.You'll also learn why strength training is non-negotiable during GLP-1 therapy or bariatric weight loss, what to know about oral semaglutide vs. injectable versions, and how nutrition plays a key role in maintaining muscle mass while losing weight.Whether you're a patient on Ozempic, Wegovy, Zepbound, or considering medication as part of your obesity treatment, this episode helps you make more informed, science-based decisions.Download our NEW FREE APP now!For Apple: https://apps.apple.com/us/app/a-pound-of-cure/id6741747271For iOS: https://play.google.com/store/apps/details?id=com.digitalbariatrics.poundofcure

VISIT ALL OUR LINKS: https://linktr.ee/manonthemounjaro

It's no exaggeration to say that the past decade has revolutionized how we think about and treat obesity. Drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) have dominated headlines, enabling significant weight loss at speeds once considered unthinkable. The market for innovative weight loss medications is booming, with pharmaceutical companies investing heavily in hopes of developing the next blockbuster drug.However, amid this race for market dominance, many experts are questioning whether the amount of weight loss alone is the best measure of these drugs' usefulness. How can the next generation of obesity treatments meaningfully improve upon the powerful options already available?Joining The Lancet editors Callam Davidson and Miriam Sabin to discuss this question is Professor Steven Heymsfield from the Pennington Biomedical Research Center. This wide-ranging conversation covers exciting pharmaceutical advances and limitations of these treatments, including the significant disparities in access, and why these breakthroughs may have broader societal implications.Send us your feedback!Read all of our content at https://www.thelancet.com/?dgcid=buzzsprout_tlv_podcast_generic_lancetCheck out all the podcasts from The Lancet Group:https://www.thelancet.com/multimedia/podcasts?dgcid=buzzsprout_tlv_podcast_generic_lancetContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

More people than ever are turning to medicine for weight loss, but how do you know if it's right for you? In this episode, I dive into the hot topic of weight loss medications and tackle the myths, science, and facts behind them. As a board-certified obesity medicine specialist, I explain who qualifies for medications like Wegovy, Zepbound, and others, how they work, and why obesity is a chronic condition, not a personal failure. I will walk you through the medical, hormonal, and genetic factors that influence treatment, outline FDA guidelines, and share how I assess whether a patient is a good candidate. I also discuss common misconceptions, long-term use, and tips for having an informed conversation with your doctor. Because remember, It's not about shortcuts, it's about finding the right tools to improve your health and quality of life. Tune in to learn the truth about weight loss medications, debunk common myths, and find out if they're the right fit for your health journey.   Episode Highlights: Who qualifies for weight loss medications FDA-approved options Common myths debunked about weight loss drugs How GLP-1 medications work and their long-term role in obesity treatment Key factors doctors assess before prescribing Contraindications and who should not take these medications How to talk to your doctor about medical weight loss options Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are reshaping how we treat obesity — but there's so much confusion and stigma. That's why we sat down with leading obesity specialist Dr. Spencer Nadolsky for an honest, empowering conversation.We break down how GLP-1s actually work, why food noise is real, and what people aren't being told about compounded semaglutide, weight regain after bariatric surgery, and long-term success.If you've felt frustrated, misunderstood, or stuck — this episode is for you. Whether you're post-op, on medication, or considering your options, this episode brings science, support, and real talk together.

If I wanted to gain back 70 pounds, I know exactly what I'd do because I've lived it. In this episode, I'm sharing the habits, behaviors, and sneaky thought patterns that kept me stuck for years…and would absolutely pack the weight back on if I let them. From zombie eating and isolating myself to living in stretchy pants and giving in to my inner fat bitch voice, we're calling it ALL out.If you've been slipping back into these patterns or feel disconnected from yourself, this episode is your wake-up call. 

This week on Good Day Health, host Doug Stephan teams up with Dr. Ken Kronhaus to unpack the latest breakthroughs in medicine, nutrition, and public health.First up, encouraging news for women with obesity: new research suggests weight-loss medications like Ozempic and Zepbound may reduce the risk of breast cancer.Then, a fascinating look at how AI is transforming modern medicine — from designing custom proteins to combat cancer and antibiotic-resistant infections, to decoding how aging truly works.Got heartburn? Dr. Ken explains why some weight-loss drugs are causing GERD-like symptoms, how to tell if you have acid reflux, and what to do about it.Confused about gluten intolerance vs. gluten allergies? Learn how they differ — and why they're often mistakenly tied to GERD.From the gardenia fruit to your Gatorade — the FDA just approved a natural blue food dye, and we're diving into what it means for your health.COVID-19 continues to follow a seasonal pattern, according to new CDC data — but what should you actually dowith that info?Plus: Is aluminum in deodorant dangerous?And should you worry about pneumonic plague after a case surfaced in Arizona?Join Doug and Dr. Ken for trusted insights, straight talk, and smart science. Call Lake Cardiology: (352) 735-1400Website: GoodDayNetworks.comSocial Media: @GoodDayNetworks

TikTok claims to have banned “SkinnyTok,” but disordered eating content continues to thrive under rebranded hashtags, edited images, and wellness culture language. In this eye-opening episode of Dr. Marianne-Land, Dr. Marianne Miller is joined by eating disorder prevention advocate and educator Jen Tomei (@askjenup) to unpack the rise of SkinnyTok and its harmful influence on teens and adults alike. Jen, founder of the Jenup Community in the UK, shares firsthand experiences of discovering disturbing content on TikTok—even after reporting and flagging videos, the algorithm continued pushing them. Together, she and Dr. Marianne draw chilling parallels to the pro-ana forums of the early 2000s, and explore how new forms of tech—including AI-edited bodies—are further distorting body image online. They also examine how neurodivergent teens, who are often more vulnerable to extreme thinking and sensory overload, may be especially impacted by these trends. Plus, they critique the rise of weight loss drugs like Ozempic and their potential to normalize restriction—even in pediatric settings. WHAT YOU'LL LEARN IN THIS EPISODE: Why SkinnyTok still exists despite being technically banned How TikTok's algorithm can push disordered content—even without user interaction What “pro-ana” and “thinspo” culture looks like in 2025 The physiological damage caused by overexercise and undereating How social media is shaping disordered eating culture in schools globally The link between ADHD, cortisol, and disordered eating behaviors How weight loss drugs like Ozempic may impact teens' mental and physical health Why media literacy and early intervention in schools are urgently needed CONTENT CAUTIONS: This episode includes discussion of disordered eating, anorexia, pro-eating disorder content, social media harm, and weight loss medications including Ozempic and Zepbound. MEET OUR GUEST: Jen Tomei is the founder of Jenup.com, a UK-based organization providing school workshops on eating disorder prevention, body image, and self-esteem. A survivor of an eating disorder and a late-diagnosed ADHD adult, Jen brings both lived experience and professional insight into the complex intersection of neurodivergence, mental health, and diet culture.

In this episode of the Irresistible You podcast, we're diving into what it means to embrace your cozy or “soft life” era, without the guilt. I used to think that doing cozy things like diamond painting or relaxing at home was lazy… or worse, that stillness would lead to weight gain. I thought if it didn't make money or burn calories, it was a waste of time. But now I know better.I'm sharing how I've started doing things that pull me rather than constantly pushing myself and how that shift has helped me stop emotional eating, feel more grounded, and finally listen to my body. Cozy isn't laziness, it's restoration.If you've ever felt stuck between hustle culture and burnout, this episode is for you.

What up, Beasts. Welcome back to the show! This week on the Unveiling the Beast podcast, I sat down with Katie Sorensen, a nurse practitioner and owner of Weight Loss NP, to dig into one of the most misunderstood topics on the internet right now: GLP-1 medications. You know, the ones people love to hate, like Ozempic and ZepBound. As someone who's been waist-deep in the research for months (because yes, that's what us nerdy, weight-neutral coaches do), I wanted to bring nuance and facts into a conversation that's gotten way too loud and way too shallow. Katie broke down what these meds actually are, how they work with your body (not against it), and why calling them “the easy way out” is just lazy and harmful. Spoiler: they've been around for decades, are made of naturally occurring peptides, and they're doing a hell of a lot more than shrinking waistlines.We also talked about the emotional weight behind physical weight, the ridiculous judgment people face for using science to support their health, and how these meds are turning down the obsessive food noise that steals so much brain space. Katie and I are both on the same page: it's not about glorifying weight loss. It's about freeing people to focus on what actually matters in life. We covered everything from muscle preservation to mental health to why strength training is the real anti-aging hack. And if you've ever looked at someone using a weekly injection and thought, “Must be nice,” this episode will shift your perspective. As always, we ended with some wisdom, and Katie's was simple and powerful: get outside, soak in the sunshine, and walk. Because sometimes, the best medicine is free and found in the fresh air.As always, I hope something lands with you today. I hope something you hear tugs at your heart strings and/or I hope you laugh.Bio: Katie Sorensen, NP-C, is a passionate Nurse Practitioner dedicated to transforming lives through her innovative and holistically focused practice, Weight Loss NP, LLC. With a mission to empower individuals to achieve optimal health and vitality, Weight Loss NP specializes in personalized medical weight loss and metabolic health solutions that deliver real and lasting results.Music by Prymary: Sean Entrikin (my hot husband) on guitar, Chris Quirarte on drums, Smiley Sean on keyboards, Rob Young on bass, and Jaxon Duane on vocals.Previous Episodes about GLP-1s151 This Might Be The Most Honest GLP-1 Conversation on the Internet154 The Science of GLP-1s and Why it's Blowing My MindGLP-1 Studies I've looked at: https://storage.googleapis.com/msgsndr/AX1su0J5xvxdddMmNWzF/media/685765ea077fba411ec88ff3.pdfConnect with Katie!Website: www.theWLNP.comYouTube: www.youtube.com/@WeightLossNPFacebook: https://www.facebook.com/weightlossnpcoWhere can you find me?Linktree: https://linktr.ee/beautifulbeastwithinstudiosWhat if health wasn't about rules or restriction?What if it felt more like trust, ease, and actually liking the person in the mirror?I help people rebuild their relationship with food, movement, and themselves, so health becomes something you live, not something you chase.Ready for a different kind of conversation? Let's talk. No pressure.https://beautifulbeastwithinstudios.com/exploration-chat-schedulingAffiliate LinksBreakthrough Coaching Certification: If you feel called to help others heal or grow, Sean Smith's Breakthrough Coaching Certification is where that calling becomes real. https://coachseansmith.ontraport.net/t?orid=27037&opid=43Opus Clip: I use Opus Clip mostly for captions, and it's a game-changer for turning long videos into usable clips. If you use my link, it supports the show, and I appreciate you big time! https://www.opus.pro/?via=1118d2Mary Kay: Grab your faves here: https://www.marykay.com/kaitienoelleUnveil the Beautiful Beast Within YOU!Zoom Background:By Behr

In this episode, we dive deep into the biggest stories shaping the markets right now. Intel has officially fallen out of the top 10 semiconductor companies — is it too late for them to catch up, and which 3 chipmakers should investors focus on instead? We also break down how stock options can be used as a powerful wealth-building tool when used the right way.With Nvidia flirting with a $4 trillion valuation after an explosive 870% AI-led rally, we discuss whether it's headed for a meltdown or another breakout — and which overlooked metric might signal what's next. Bitcoin also hit a new all-time high heading into Crypto Week, and we break down what this means for the broader crypto market.Next, we analyze who the real winners and losers in Big Tech have been since Trump took office, and what it means for investors moving forward. With U.S. equity fund inflows collapsing from $31.6 billion to just $2.1 billion, we ask: are you buying the dip or parking cash on the sidelines? Lastly, we look at Eli Lilly and whether its new Zepbound pill could drive a potential 40% surge in the stock over the next year.EYLU 24 Hour 50% off Sale (Code: Marketmondays) https://eyluniversity.comInvest Fest Ticket Link: https://investfest.com#Investing #StockMarket #Crypto #Bitcoin #Nvidia #Intel #EliLilly #Zepbound #TechStocks #InvestFest #EarnYourLeisure #MarketMondays #FinancialFreedom #OptionsTradingOur Sponsors:* Check out PNC Bank: https://www.pnc.comSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Driveway Beers PodcastWeight Loss and The Yukon!!We've been saying that we'd update you on our weight loss for 3 episodes now and we failed to come through. But this week, we fullfill the promise and give an update on Mike and Alex's weight loss (or gains) since the last episode. And the saga of the 04 Yukon Denali continues. Did Alex finally get it sorted out?? Why won't he just buy a new car already?? #cars #suv #weight #loss #weightloss #health #ozempic #zepbound #drugs #conservative #liberal #GeneralMotors #autos Please subscribe and rate this podcast on your podcast platforms like Apple and Spotify as it helps us a ton. Also like, comment, subscribe and share the video on Youtube. It really helps us get the show out to more people. We hope you enjoyed your time with us and we look forward to seeing you next time. Please visit us at https://drivewaybeerspodcast.com/donate/ to join The Driveway Club and buy us a bourbon! Buy us a bottle and we'll review it on a show!Leave us a comment and join the conversation on our discord at https://discord.gg/rN25SbjUSZ.Please visit our sponsors:Adam Chubbuck of Team Alpha Charlie Real Estate, 8221 Ritchie Hwy, Pasadena, MD 21122, www.tacmd.com, (443) 457-9524. If you want a real estate agent that will treat your money like it's his own and provide you the best service as a buyer or seller, contact Adam at Team Alpha Charlie.If you want to sponsor the show, contact us at contact@drivewaybeerspodcast.comCheck out all our links here https://linktr.ee/drivewaybeerspodcast.comIf you're looking for sports betting picks, go to conncretelocks.com or send a message to Jeremy Conn at Jconn22@gmail.comFacebook Page https://www.facebook.com/drivewaybeerspodcast/#podcast #whiskey #bourbon

Did you know that stopping GLP-1 medications like Ozempic or Wegovy can trigger powerful biological and emotional changes that impact your weight journey? In this episode, I talk about what happens when you stop taking a GLP-1 medication, like Ozempic, Wegovy, or Zepbound. I explain how these medications work by slowing stomach emptying, reducing appetite, and helping with insulin regulation, which supports weight loss and benefits conditions like type 2 diabetes and PCOS. However, I also share that they're not magic pills, you still need healthy habits like eating well and exercising. I highlight possible side effects, such as nausea or pancreatitis risks, and emphasize that stopping these medications can lead to increased hunger, cravings, weight regain, and even emotional distress. But I also reassure you that this isn't a sign of failure. Weight regain is often biological, not personal. I offer tips for tapering off safely, reinforcing lifestyle habits, and exploring other options. Most importantly, I remind you that your journey is valid, you're not alone, and lasting success requires a plan, support, and self-compassion. Tune in to learn what really happens when you stop taking GLP-1 medications—and how to stay empowered and in control of your weight journey.   Episode Highlights: How GLP-1 medications like Ozempic and Wegovy work Common side effects and safety considerations What to expect when stopping GLP-1s, both physically and emotionally Strategies to manage weight regain and maintain healthy habits Alternative tools and support options beyond medication Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? This week, we pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand. Featuring: Principal Analysts Caroline Chumakov and Jenna Fink.Contextualizing the appetite for GLP-1s (0:46)Build, buy, acquire: How Novo Nordisk and Eli Lilly are meeting demand (04:05)The implications of Novo Nordisk's $16.5 billion Catalent acquisition (05:53)How to decide whether to acquire or outsource (07:23)Where in the world is GLP-1 manufacturing going next? (10:36)DTC, telehealth, and the future of GLP-1 channel strategy (13:16)How AI is driving pharma innovation at Novo Nordisk, Eli Lilly, Johnson & Johnson, and Merck (17:13)

Skinny Bones: An Overlooked Risk of Modern Weight Loss TreatmentIf you're considering or already using weight loss injections like Ozempic, Zepbound,  or Wegovy, this is a conversation you can't afford to miss.In under 8 minutes, this episode of Dr. Pepper...Really? will open your eyes to a little-known health concern hiding behind the weight loss hype—bone loss. Host Dr. Gary Pepper, a seasoned endocrinologist, introduces Linda, a postmenopausal woman weighing her options, to explore the deeper risks tied to rapid weight reduction.What you'll learn:Why losing weight quickly—especially after menopause—could accelerate bone thinningThe silent risk of fractures and the shocking reality of post-fracture outcomesWhy the FDA doesn't require bone safety data in weight loss drug trialsWhat simple screening and prevention steps you should be taking nowHow to protect yourself from malnutrition and bone loss with the right tools and knowledgeUnlike typical wellness advice, this podcast digs into the real science and unspoken gaps in our current weight loss culture. It's not about fear—it's about informed choices. You'll walk away with practical strategies and a new perspective on how to lose weight without losing your health.The podcast also introduces listeners to semagludiet.com, a one-stop resource designed to support people using GLP-1 medications. The site features free tools, meal plans, and the CSS Diet System—an innovative plate and bowl set that promotes portion control while maintaining nutrient density, helping you preserve muscle and bone during weight loss.This conversation also highlights the role of metabolism.com and the Dr. Pepper...Really? podcast in giving voice to medical concerns that often fly under the radar. When public messaging from pharmaceutical companies or regulators fails to capture the full picture, we step in to fill the gap with real talk backed by medical insight.And if you're wondering why you haven't heard this anywhere else, you're not alone. The lack of public awareness may not be accidental—but this podcast isn't about finger-pointing. It's about empowerment through information.Whether you're a healthcare consumer, a concerned friend, or just curious about what's really going on behind the headlines, this episode will change how you view weight loss treatments—and what questions you should be asking next.Disclaimer: This podcast is for informational purposes only and does not constitute medical advice. Please consult your personal healthcare provider for diagnosis and treatment decisions.Portions of this episode have been enhanced using artificial intelligence to optimGary Pepper, M.D., an associate professor at a prominent medical school and endocrinologist with 40 years of experience, brings clarity to numerous topics within the field of metabolic health. His view points are unhindered by corporate interests, unlike many other current "thought leaders" in medicine. Dr. Pepper, a dedicated educator, established his homebase website www.metabolism.com in 1996 and has blogged on important topics since then. Not one to be left behind by technology he began podcasting in 2020 with the onset of the pandemic and continues publishing vlogs on YouTube at his channel metabolism123. So whatever your choice in media, you will be gaining fresh insights by tuning in to his opinionated shows or reading his blogs on critical health topics.

VA cuts coming. The government's role is not to create jobs for people. CVS dropping Zepbound. What will Lilly's response be? Leftist loons compare ICE detention centers to concentration camps. Edgewood High School Sign for your car on the marketplace $800. Time to impeach Justice JacksonSee omnystudio.com/listener for privacy information.

Parents don't let your kids out late to shoot others. Trump sending weapons to Ukraine, after days before he said he wouldn't be sending weapons. Rift on the White House? Trump 8-1 SCOTUS win, guess who dissented? Public broadcasting cuts have arrived in Indiana. Honda unplugging SUV EV's. VA cuts coming. The government's role is not to create jobs for people. CVS dropping Zepbound. What will Lilly's response be? Leftist loons compare ICE detention centers to concentration camps. Edgewood High School Sign for your car on the marketplace $800. Time to impeach Justice Jackson. The Trolls are out. Tony tells Tara about them. Death toll in Texas is horrific. Home sellers are quitting the market. Now they are dangling the prosecutions of Comey and Brennan to try and make us forget about Epstein. Trump to tariff imported copper and pharmaceuticals? Caitlin Clark returns to the court today at Noon. Clark sells out seats, not Angel Reese.See omnystudio.com/listener for privacy information.

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Have you ever wondered why some people seem to drop weight quickly on medications like Wegovy or Zepbound, while others barely budge?The truth is, weight loss isn't as simple as eating less or moving more and even powerful medications don't work the same for everyone. Results often depend on how these drugs are used, the lifestyle habits that support them, and individual factors like metabolism, other health conditions, and how well the body tolerates treatment.That's why it's important to rethink what “success” really means. For many, losing just 5% to 10% of body weight can make a huge difference, improving blood sugar, blood pressure, and cholesterol enough to lower the risk of serious health issues—even if the scale doesn't land exactly where they hoped.In this episode, we'll cover:What success really looks like on Wegovy or ZepboundWhy type 2 diabetes makes weight loss harder, even with GLP-1sHow alcohol use is one of the top reasons people don't see expected resultsThe role of habit snacking and how it can stall progressWhat to do when side effects get in the wayWhen these medications alone aren't enoughAnd what to explore if nothing seems to be workingHit play to find out the top reasons people fall short on Wegovy or Zepbound, how to spot them, and what might finally help you see progress.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.co

Send us a message with this link, we would love to hear from you. Standard message rates may apply.On this episode discuss the side effects of GLP-1 medications like Ozempic and Wegovy, Zepbound, and Mounjaro offering practical strategies to manage these effects while still benefiting from the medications.• GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) help manage type 2 diabetes, obesity, and can reduce cardiovascular risk• Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, bloating, and constipation• "Sulfur burps" are a frequently reported side effect that some manage with Pepto-Bismol• Start with low doses and increase slowly to minimize side effects• Eat smaller portions, avoid greasy/spicy foods, and practice mindful eating to reduce GI symptoms• Stay hydrated and increase fiber intake to prevent constipation• Gallbladder problems and pancreatitis risk may increase with rapid weight loss• Some evidence suggests potential vision changes requiring regular eye check-ups• Medications like insulin or blood pressure drugs may need adjustment when on GLP-1s• Most side effects improve with time as your body adjusts to the medicationSend us an email at yourcheckuppod@gmail.com or visit our Instagram or website to stay updated with weekly episodes released every Monday.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

GLP-1's are tools and if you don't use them well, there's a cost. I'm a registered dietitian, speaker and author who works in the weight loss and GLP-1 space. Here are the 3 most important nutrition pitfalls to avoid if you want to feel your best on a GLP-1 like Ozempic, Mounjaro, Zepbound, & Wegovy.

Is there a better, safer, FREE alternative to Ozempic (and other GLP-1 drugs)? In this episode of Walk, Don't Run to the Doctor, Miles Hassell MD reacts to the growing buzz and shares a time-tested, evidence-based 3-step plan that outperforms popular weight loss drugs in the long run. As GLP-1 drugs like Ozempic, Wegovy, and Mounjaro surge in popularity, Dr. Hassell offers critical insight into their risks—like muscle loss, pancreatic complications, and long-term unknowns—while proposing a practical, natural alternative for lasting weight loss and better metabolic health. Key Takeaways: Why Big Pharma's track record with weight loss drugs demands caution The secret 3-step plan: Eat 6 servings of fruits & veggies, 3 minutes of daily exercise, reduce refined carbs Bonus tips: Bust cravings by eating protein with every meal, daily probiotics, and unlock the power of preemptive eating Why this plan costs nothing, has zero side effects, and starts showing results in just one week A timely message in light of the weight loss drug headlines—who should be in control of your health?  More references can be found at www.GreatMed.org Get your copy of Good Food Great Medicine. https://a.co/d/ajAzYzo Would you like Dr. Hassell to answer your question on the air? Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter. We love to hear from you. This podcast is sponsored by our generous listeners. Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229 References: Chen, X., et al. (2025). Association of dietary fiber intake with all-cause and cardiovascular mortality in diabetes and prediabetes. Diabetology & metabolic syndrome, 17(1), 231. https://pubmed.ncbi.nlm.nih.gov/40533827/   Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, obesity & metabolism, 27(5), 2720–2729. https://pubmed.ncbi.nlm.nih.gov/39996356/   Wilding, J., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/   Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society, 8(11),https://pubmed.ncbi.nlm.nih.gov/39372917/    Neeland, I. J., et al. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, obesity & metabolism, 26 Suppl 4, 16–27. https://pubmed.ncbi.nlm.nih.gov/38937282/   Sato, M., et al. (2023). Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study. Journal of clinical medicine, 12(9), 3104. https://pubmed.ncbi.nlm.nih.gov/37176545/   Monami, M., et al. (2017). Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes, obesity & metabolism, 19(9), 1233–1241. https://pubmed.ncbi.nlm.nih.gov/28244632/   Anderson, S. L., & Trujillo, J. M. (2010). Association of pancreatitis with glucagon-like peptide-1 agonist use. The Annals of pharmacotherapy, 44(5), 904–909. https://pubmed.ncbi.nlm.nih.gov/20371755/   Kapoor, I., Sarvepalli, S. M., D'Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of ophthalmology, 68(6), 1071–1083. https://pubmed.ncbi.nlm.nih.gov/37454782/   Bikou, A., et al. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert opinion on pharmacotherapy, 25(5), 611–619. https://pubmed.ncbi.nlm.nih.gov/38629387/   Jalleh, R. J., et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of clinical endocrinology and metabolism, 110(1), 1–15. https://pubmed.ncbi.nlm.nih.gov/39418085/   Berg, S. AMA. (2023). Questions patients may have about weight-loss drugs. https://www.ama-assn.org/delivering-care/public-health/questions-patients-may-have-about-weight-loss-drugs   Friedman, J. (2025). America's up-and-down history with weight-loss drugs. https://www.history.com/articles/weight-loss-drugs-america    

Let's be honest, everyone's talking about GLP-1s (Ozempic, Wegovy, Zepbound), but no one's telling the whole story. Until now.This week, we're joined by the brilliant Dr. Alexandra Sowa—board-certified physician, NYU clinical instructor, founder of SoWell, and author of The Ozempic Revolution—for the ultimate deep dive into everything you actually need to know about navigating life on (and off) GLP-1s. From weight loss plateaus and blood sugar crashes to the infamous “Ozempic face,” nothing is off-limits. We break down the stigma, the science, and why it's not about getting thin—it's about getting healthy. We also unpack the tests your doctor probably isn't running (but should), the supplements that can make or break your progress, and why most people are doing GLP-1s totally wrong. Whether you're curious, committed, or just confused, this episode is your go-to guide to understanding your metabolism, hormones, and long-term health—without shame and without shortcuts. Mentioned in the Episode: SoWell GLP-1 Support System  The Ozempic Revolution by Dr. Alexandra Sowa HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) Calculator GLP-1 Medication Insurance Toolkit Your Friends & Neighbors (Apple TV) SoWell Electrolytes A Sony Music Entertainment production.  Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts  To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________Dr. David Kessler, former FDA Commissioner and author of Diet, Drugs, and Dopamine, joins us to break down the science behind food addiction, obesity, and GLP-1 medications like Ozempic and Zepbound.He doesn't just study this—he lives it. Dr. Kessler has obesity, takes GLP-1s, and knows firsthand what it's like to battle food noise and weight stigma.In this episode, we discuss:What makes ultra-processed food addictiveHow GLP-1s affect the brain and reduce cravingsWhether some people can stop taking GLP-1sHis personal experience starting, stopping, and restartingWhy weight regain happens and what the body is really fightingHis bold policy ideas to regulate Big Food like Big TobaccoDr. Kessler helped bring HIV drugs to market faster, led Operation Warp Speed, and took on the tobacco industry. Now, he's focused on the next public health crisis: food addiction and obesity.Subscribe to The Plus SideZ Podcast for more expert conversations on GLP-1s, weight, and wellness.Specialist and Community Guest Dr. David KesslerBIO: David. A. Kessler, MD, served as chief science officer of the WhiteHouse COVID-19 Response Team under President Joe Biden and previouslyserved as commissioner of the US Food and Drug Administration underPresidents George H.W. Bush and Bill Clinton. He is the author of the_New York Times_ bestsellers _The End of Overeating_ and_ Capture_ andtwo other books:_ Fast Carbs, Slow Carbs_ and _A Question of Intent_.Dr. Kessler is a pediatrician and has been the dean of the medicalschools at Yale and the University of California, San Francisco. He is agraduate of Amherst College, the University of Chicago Law School, andHarvard Medical School.Social Media:https://x.com/DavidAKesslerMDLink to Book:https://www.audible.com/pd/B0D5KS9P4D?source_code=ASSORAP0511160006&share_location=pdpSpecial community guest Mike on a Health Mission Social MedSend us Fan Mail! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #zepbound #insurance #cvscaremark

Welcome back to Diamond Paint and Podcast — where I ramble, reflect, and real-talk my way through a diamond painting session.In this episode, we're all over the place in the best way possible. I'm chatting about:The “Donut Mom” at cheerleading

Americans are unusually overweight and chronically ill compared to similarly rich countries. This episode presents a grand, unified theory for why that's the case. Our food environment has become significantly more calorie-rich and industrialized in the past few decades, sending our obesity rates soaring, our visceral fat levels rising, and our chronic inflammation surging. The result is an astonishing rise in chronic illness in America. That's the bad news. The good news is that GLP-1 drugs, like Ozempic and Zepbound, seem to be astonishingly successful at reversing many of these trends. This episode blends two interviews with Dr. David Kessler and Dr. Eric Topol. Kessler was the commissioner of the Food and Drug Administration under the Bush and Clinton administrations, from 1990 to 1997. He helped lead Operation Warp Speed in its final months. He is the author of the book 'Diet, Drugs, and Dopamine.' Topol is a cardiologist and the founder and director of the Scripps Research Translational Institute. He is the author of the book 'Super Agers.' If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: Dr. David Kessler and Dr. Eric Topol Producer: Devon Baroldi Learn more about your ad choices. Visit podcastchoices.com/adchoices